Peter Lynch saw a bet payoff yesterday when Sirtris Pharmaceuticals completed its IPO with a nine percent gain. Sirtris [NASDAQ: SIRT] had disclosed that "entities associated" with Lynch invested in preferred shares earlier this year. The size of the famed Fidelity fund manager's stake has not been disclosed by Sirtris. The drug maker is focused on developing treatments for diseases associated with aging. 

Stay ahead of the news ... Sign up for our email alerts now
CLICK HERE